series-b
Stage
1
Investors
About
COUR Pharma develops targeted antigen-specific therapies that reprogram the immune system to treat autoimmune diseases, with clinical trials underway for Type 1 Diabetes and Myasthenia Gravis.
Explore COUR Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.